Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Liquidia Corp Chief Accounting Officer Dana Boyle reported routine equity compensation activity and a small open-market sale. On April 10, 2026, Boyle exercised 3,179 Performance Stock Units, converting them into the same number of shares of common stock at a conversion price of $0.00 per share.
On April 13, 2026, Boyle sold 5,101 shares of Liquidia common stock at an average price of $38.37 per share under a Rule 10b5-1 trading plan. According to the filing, these shares were sold to cover taxes associated with the settlement of previously granted RSUs and PSUs. After these transactions, Boyle directly holds 176,918 shares of common stock, along with multiple tranches of unvested RSUs and PSUs that continue to vest over time.
Liquidia Corp CFO and COO Michael Kaseta reported multiple equity transactions in company stock. On April 10, 2026, he exercised 23,821 stock options at $2.79 per share and converted 5,828 and 7,050 Performance Stock Units into common shares on a one-for-one basis. He then sold 23,821 common shares in the open market at a volume weighted average price of $40.1431, pursuant to a Rule 10b5-1 trading plan.
On April 13, 2026, Kaseta sold an additional 18,958 common shares at $38.37 per share, with footnotes stating these shares were sold to cover taxes tied to RSU and PSU settlements and effected under a Rule 10b5-1 plan. After these transactions, he directly holds 405,775 common shares, along with substantial unvested RSUs and PSUs and 11,694 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corp Chief Human Resource Officer Sarah Krepp reported a combination of equity award activity and a small share sale. She exercised 3,179 performance stock units, which converted to the same number of common shares at a $0.00 exercise price, reflecting previously granted compensation vesting. On a separate date, she sold 4,557 common shares in an open-market transaction at $38.37 per share under a pre-arranged Rule 10b5-1 plan, with the filing noting the sale was to cover taxes from RSU and PSU settlements. After these transactions, she directly holds 147,019 common shares and continues to have sizable unvested RSU and PSU awards scheduled to vest over several years.
Liquidia Corp Chief Medical Officer Rajeev Saggar reported multiple equity transactions. He exercised 8,017 performance stock units that converted into the same number of shares of common stock at an exercise price of $0.00 per share. On a later date, he sold 9,220 shares of common stock in an open-market transaction at $38.37 per share, pursuant to a pre-arranged Rule 10b5-1 plan. According to the footnotes, these shares were sold to cover taxes associated with the settlement of previously granted RSUs and PSUs. After these transactions, he directly owned 173,270 shares of common stock, alongside various unvested RSUs and PSUs granted in prior years.
Liquidia Corp General Counsel Russell Schundler reported both equity awards vesting and a small share sale. He exercised performance stock units into a total of 10,167 shares of common stock at an exercise price of $0.00 per share.
On April 13, 2026, he sold 13,692 shares of common stock in an open-market transaction at $38.37 per share under a pre-arranged Rule 10b5-1 trading plan. According to the footnotes, these shares were sold to cover taxes tied to earlier RSU and PSU settlements. After these transactions, he directly holds 610,532 shares of Liquidia common stock and indirectly holds 14,500 shares through his spouse.
Liquidia Corp Chief Executive Officer Roger Jeffs reported a mix of equity vesting and share sales. He exercised performance stock units that converted into 28,167 shares of common stock at a conversion price of $0.00 per share, reflecting compensation-based awards rather than market purchases.
On the same date, 21,433 common shares were sold at a volume-weighted average price of $40.1193 per share through Serendipity BioPharma LLC, which Jeffs manages, with sole voting and dispositive power. A footnote states these shares were sold to cover taxes on vested RSUs and PSUs pursuant to a Rule 10b5-1 plan. Separately, he later sold 32,744 directly held shares at $38.37 per share under another Rule 10b5-1 trading plan and continued to hold 1,137,599 common shares directly afterward.
Insider sale notice: A Form 144 for LQDA reports an intended sale of 3,000 shares via exercise of stock options on 04/14/2026 for cash. The filing also lists recent Rule 10b5-1 sales by Michael Kaseta: 23,821 shares on 04/10/2026 for $956,248.79, 133,789 shares on 04/09/2026 for $5,383,388.40, and 1,165 shares on 03/02/2026 for $35,625.70.
Liquidia Corp Chief Executive Officer Roger Jeffs reported an open-market sale of 25,000 shares of Common Stock at an average price of $40.1155 per share. The transaction was executed indirectly through an affiliated entity and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025.
After the sale, Jeffs has 1,142,176 shares held directly and additional indirect holdings of 1,516,667 and 46,595 shares through entities associated with him. Footnotes also note substantial unvested RSU awards from grants made between January 2023 and January 2026, and that 10,696 shares previously acquired under the company’s Employee Stock Purchase Plan were rescinded due to ineligibility.
Liquidia Corp CFO and COO Michael Kaseta reported an exercise-and-sell transaction in company stock. He exercised stock options covering a total of 133,789 shares of common stock at exercise prices ranging from $2.54 to $2.97 per share and then sold 133,789 shares at a volume-weighted average price of $40.2379 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. After these transactions, he directly holds 411,855 shares of common stock, which include various blocks of unvested restricted stock units and shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
Serendipity Biopharma LLC filed a Rule 144 notice reporting resale activity in common stock. The filing lists 10b5-1 sales: 25,000 shares sold on 04/09/2026 for $1,002,887.50 and an earlier sale of 66,610 shares on 01/12/2026 for $2,493,212.30. The broker listed is Morgan Stanley Smith Barney LLC and the filing references NASDAQ.